A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough Including Unexplained Chronic Cough (CALM-2)

Project Details

StatusActive
Effective start/end date2/01/23 → 5/01/26

Funding

  • IQVIA RDS Pty. Limited: A$105,766.00